TMPRSS2-ERG gene fusion is rare compared to PTEN deletions in stage T1a prostate cancer

Authors

Kurt W. Fisher
Shaobo ZhangFollow
Mingsheng WangFollow
Rodolfo Montironi
Lisha WangFollow
Lee A. Baldrige
Jonas Y. Wang
Gregory T. MacLennan
Sean R. Williamson, Henry Ford HealthFollow
Antonio Lopez-Beltran
Liang Cheng

Recommended Citation

Fisher KW, Zhang S, Wang M, Montironi R, Wang L, Baldrige LA, Wang JY, MacLennan GT, Williamson SR, Lopez-Beltran A, Cheng L. TMPRSS2-ERG gene fusion is rare compared to PTEN deletions in stage T1a prostate cancer. Mol Carcinog. 2017 Mar;56(3):814-820.

Document Type

Article

Publication Date

3-1-2017

Publication Title

Molecular carcinogenesis

Keywords

Aged, Aged, 80 and over, Gene Deletion, Gene Expression Regulation, Neoplastic, Humans, In Situ Hybridization, Fluorescence, Male, Middle Aged, Neoplasm Staging, Oncogene Proteins, Fusion, PTEN Phosphohydrolase, Prostatic Neoplasms

Abstract

T1a prostate cancers (cancer found incidentally in transurethral resection,

Medical Subject Headings

Aged; Aged, 80 and over; Gene Deletion; Gene Expression Regulation, Neoplastic; Humans; In Situ Hybridization, Fluorescence; Male; Middle Aged; Neoplasm Staging; Oncogene Proteins, Fusion; PTEN Phosphohydrolase; Prostatic Neoplasms

PubMed ID

27500376

Volume

56

Issue

3

First Page

814

Last Page

820